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Background: The PENPACT-1 trial compared virologic thresholds
to determine when to switch to second-line antiretroviral therapy
(ART). Using PENPACT-1 data, we aimed to describe HIV-1 drug
resistance accumulation on first-line ART by virologic threshold.
Methods: PENPACT-1 had a 2 · 2 factorial design, randomizing
HIV-infected children to start protease inhibitor (PI) versus nonnucleo-
side reverse transcriptase inhibitor (NNRTI)-based ART, and switch at
a 1000 copies/mL versus 30,000 copies/mL threshold. Switch criteria
were not achieving the threshold by week 24, confirmed rebound above
the threshold thereafter, or Center for Disease Control and Prevention
stage C event. Resistance tests were performed on samples $1000
copies/mL before switch, resuppression, and at 4-years/trial end.
Results: Sixty-seven children started PI-based ART and were
randomized to switch at 1000 copies/mL (PI-1000), 64 PIs and
30,000 copies/mL (PI-30,000), 67 NNRTIs and 1000 copies/mL
(NNRTI-1000), and 65 NNRTI and 30,000 copies/mL (NNRTI-
30,000). Ninety-four (36%) children reached the 1000 copies/mL
switch criteria during 5-year follow-up. In 30,000 copies/mL threshold
arms, median time from 1000 to 30,000 copies/mL switch criteria was
58 (PI) versus 80 (NNRTI) weeks (P = 0.81). In NNRTI-30,000, more
nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations
accumulated than other groups. NNRTI mutations were selected before
switching at 1000 copies/mL (23% NNRTI-1000, 27% NNRTI-
30,000). Sixty-two children started abacavir + lamivudine, 166
lamivudine + zidovudine or stavudine, and 35 other NRTIs. The
abacavir + lamivudine group acquired fewest NRTI mutations. Of 60
switched to second-line, 79% PI-1000, 63% PI-30,000, 64% NNRTI-
1000, and 100% NNRTI-30,000 were,400 copies/mL 24 weeks later.
Conclusions: Children on first-line NNRTI-based ART who were
randomized to switch at a higher virologic threshold developed the
most resistance, yet resuppressed on second-line. An abacavir +
lamivudine NRTI combination seemed protective against develop-
ment of NRTI resistance.
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INTRODUCTION
Pediatric guidelines1–3 recommend HIV-1–infected chil-
dren initiate antiretroviral therapy (ART) early in life. Since
ART dramatically reduces mortality, the duration of this
treatment is likely to be long, potentially for many decades.
Historically, children have tended to be maintained on failing
therapies longer than adults, due to challenges with adherence
and limited treatment options. This is particularly true in
resource-limited settings where HIV-1 RNA monitoring is
generally not available. HIV-1 drug resistance is known to
increase with continuation of the same ART regimen in the
presence of detectable viremia. Therefore, long-term treatment
success requires effective first-line therapies, minimization of
resistant virus on these therapies, and preservation of second-
line options. Careful consideration is required when sequenc-
ing ART regimens, taking into account first-line ART
exposure, acquisition of resistance mutations on first-line,
and exposure to ART as part of programs to reduce mother
to child transmission (MTCT).
The PENPACT-1 trial4 is the only long-term strategy
trial in children or adults to assess effectiveness of first-line
ART regimens and randomized RNA thresholds (1000 or
30,000 copies/mL) to determine when to switch to second-
line. Over time, a 1000-copies/mL threshold has been adopted
to define virologic failure, followed by prompt switch to
second-line in adults, but direct evidence for this threshold
remains weak. When PENPACT-1 was designed in the early
2000s, drug choice for children was limited, and switch to
second-line could be delayed due to concerns that drug
options would be quickly exhausted; therefore, a threshold
;1.5 log10 copies/mL higher than 1000 copies/mL, above
assay variation, was chosen to reflect practice at the time. In
children, current recommendations for when to switch still
vary, with the consolidated WHO guidelines1 recommending
a switch time consistent with adults and the United States and
European guidelines2,3 instead recommending assessment of
reasons for virologic failure and consideration of drug
availability, resistance profiles, adherence issues, and readi-
ness of the family/child to switch.
Using data on all children from PENPACT-1, we
explored resistance profiles after first-line ART by random-
ized switch-criteria based on RNA threshold, as well as
second-line treatment response and drug options in children.
The hypothesis was that more resistance mutations would
accumulate on first-line ART in children randomized to the
higher threshold, and this would influence second-line
response and available second-line drug options.
METHODS
PENPACT-1 was a multicenter phase 2/3, randomized,
open-label, 2 by 2 factorial trial enrolling HIV-1–infected
children from clinical centers in Europe and North and South
America, with a minimum follow-up of 4 years.4 Children were
naïve to ART, although infants who had received ,56 days of
ART to reduce MTCT were eligible. Children were simulta-
neously randomized to start ART with 2 nucleoside reverse
transcriptase inhibitors (NRTIs) plus either a protease inhibitor
(PI) or a nonnucleoside reverse transcriptase inhibitor (NNRTI)
and to switch from first-line to second-line ART at an RNA
threshold of 1000 copies/mL (low threshold) or 30,000
copies/mL (higher threshold). First-line ART was defined as
the initial regimen, allowing drug substitutions (ideally within
the same class) for nonvirologic reasons (eg, toxicity). The
initial regimen was chosen by the treating clinician according to
the randomized group. Children were switched to second-line if
the RNA threshold (,1000 or ,30,000 copies/mL) was not
achieved by week 24, or if after an initial decline in RNA by
week 24, there was a confirmed RNA rebound at/above the
randomized threshold. Switch to second-line was also required
if the child experienced a new Center for Disease Control and
Prevention stage C event at/after week 24. For analysis
purposes, children were defined in both arms as reaching the
“1000 criteria” and “30,000 criteria” using the above definition.
Children who received first-line containing a PI were strongly
encouraged to switch to a second-line containing an NNRTI
and vice versa. Children had RNA measured at enrollment,
weeks 8, 16, 24, and then 12 weekly until the last enrolled child
reached 4 years.
Baseline resistance tests were performed on samples
collected within 84 days before randomization. During
follow-up, the overall aim was to evaluate new HIV-1 drug
resistance mutations accumulated on first-line. As children
were randomized to early (low threshold) versus later (higher
threshold) switch points, requirements for resistance testing
aimed to identify additional mutations accumulated if a policy
to switch at the “30,000 criteria” compared with the “1000
criteria” was applied. To capture this, resistance tests were
required in both RNA threshold arms, while children were on
ART, at (1) the last sample with RNA $1000 copies/mL
before switch, (2) the last sample after confirmed RNA $1000
copies/mL (eg, if not switched because “30,000 criteria” not
met and RNA resuppressed to ,1000 copies/mL), and (3)
samples with RNA $1000 copies/mL at 4 years or trial end.
To further visualize the requirements for switch and resistance
testing, we have provided a Supplemental Digital Content
Figure (available at http://links.lww.com/QAI/A682) display-
ing a set of example RNA profiles. It can be seen that children
in the higher-threshold arm would be tested later when we
hypothesize more resistance mutations will have accumulated.
It can also be noted, that some RNA profiles required multiple
tests per child. Major resistance mutations were defined
according to International AIDS Society-USA guidelines.5
New mutations on first-line were accumulated over postbase-
line tests.6 Susceptibility to specific ART drugs was defined as
fully susceptible, potential low-level, low-level, intermediate-,
and high-level resistance by the genotypic resistance interpre-
tation algorithm available on the Stanford University HIV
drug resistance database Webpage.7 Genotypic sensitivity
from this algorithm was formulated for current WHO recom-
mended second-lines.
In this analysis, unlike the primary publication,4
4 children who started a drug class (PI or NNRTI) different
to their randomization were grouped based on the drug class
actually started, rather than the strict intent-to-treat defini-
tion based on randomized class. Proportions of children
reaching criteria were tested using x2 tests, time to reach
switch criteria and to actual switch used Kaplan–Meier
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methods and log-rank tests, and comparison of time to
resistance tests and RNA levels used Wilcoxon rank-sum
tests. Poisson regression, without a time offset, tested
differences in number of mutations by group. The model
assumed children not requiring resistance tests did not
develop mutations and excluded those with missing test
results. For second-line efficacy, a child was considered
successful if they achieved ,400 copies/mL 24 weeks after
switch. Proportions of children ,400 copies/mL were
calculated from Kaplan–Meier curves and comparisons used
Cox regression. Analysis used Stata statistical software.
RESULTS
Baseline Characteristics and First-Line ART
Table 1 shows baseline age, HIV-1 RNA, resistance,
HIV-1 subtype, previous ART use for reduction of MTCT,
and first-line ART for the 263 children enrolled in
PENPACT-1 initiating therapy and included in this analysis.
Other baseline characteristics have previously been pub-
lished.4 Median (range) age at start of ART was 6.5 (0.1–
17.8) years. Thirty-nine children (15%) received ART for
reduction of MTCT; most zidovudine prophylaxis alone and
only 5 (2%) received single-dose nevirapine. Four percent
(10/239) of baseline samples tested retrospectively had $1
major mutation. Of children starting PI-based ART, 65
(50%) started lopinavir/ritonavir and 64 (49%) nelfinavir,
whereas for children starting NNRTIs, 82 (62%) started
efavirenz and 50 (38%) nevirapine. For NRTIs, 166 (63%)
initiated lamivudine + zidovudine or stavudine, 62 (24%)
abacavir + lamivudine, and 35 (13%) other NRTI combina-
tions (mainly lamivudine + didanosine).
Children Reaching the 1000 and 30,000
copies/mL Switching Criteria
By trial end, at a median follow-up of 5.0 years
(interquartile range, 4.2–6.0), 94 children (36%) had
reached the “1000 criteria” (51 low threshold, 43 higher
threshold, x2 P = 0.42). These 94 children were evenly
distributed by drug class; 51 (54%) started PIs and 43
(46%) NNRTIs (x2 P = 0.42). Median RNA when the
“1000 criteria” were met was 13,505 copies/mL for those
on PIs and 9800 copies/mL for NNRTIs (Wilcoxon rank-
sum P = 0.49). As expected, most children in the low-
threshold arm switched soon after reaching the “1000
criteria” (median time to switch after reaching “1000
criteria”: 12 weeks). This time was similar in children
starting PIs (12 weeks) and NNRTIs (8 weeks, log-rank P =
0.60) (Fig. 1, solid line). Of 43 children in the higher-
threshold arm who reached the “1000 criteria”, 3 (7%)
switched before subsequently reaching the “30,000 crite-
ria,” 22 (55%) reached the “30,000 criteria” before trial end
(18 switched), and the remaining 18 (42%) neither reached
the “30,000 criteria” nor switched. The median time from
reaching the “1000 criteria” to the “30,000 criteria” was 80
weeks (Fig. 1, dotted dashed line). This observed time was
longer for those starting NNRTIs (median 80 weeks)
compared with PIs (median 58 weeks), although not
significantly different (log-rank P = 0.81). However, there
was an observed shorter time from reaching the “1000
criteria” to switch for those on NNRTIs (25th percentile: 17
weeks) compared with PIs (25th percentile: 63 weeks, log-
rank P = 0.16) (Fig. 1, solid dashed line). The median RNA
when the “30,000 criteria” were met was 54,991 copies/mL
(NNRTIs 44,550 copies/mL versus PIs 69,649 copies/mL,
Wilcoxon rank-sum P = 0.09).
Resistance Tests Required and Performed
In total, 107 children required resistance tests
(Table 2). This included 90/94 children reaching the 1000
criteria and 17 additional children. The 4 children reaching
the “1000 criteria” not requiring tests were due to 1 child
switching at a Center for Disease Control and Prevention
stage C event with suppressed RNA and 3 being off ART for
all RNAs $1000 copies/mL. The 17 additional tests were
due to single RNA $1000 copies/mL at 4 years, trial end or
before switch. These 107 children required 127 tests on first-
line; 90 (84%) required 1 test, 14 (13%) 2 tests, and 3 (3%) 3
tests. The reasons for requiring resistance tests were (1) last
sample with RNA $1000 copies/mL before switch (n = 58),
(2) last sample after confirmed RNA $1000 copies/mL (eg, if
not switched because “30,000 criteria” not met and RNA
resuppressed to ,1000 copies/mL) (n = 24), and (3) samples
with RNA $1000 copies/mL at 4 years or trial end (n = 45)
(see Figure, Supplemental Digital Content, http://links.lww.
com/QAI/A682 for example RNA profiles and resistance
testing requirements). Overall, 101/127 (80%) tests were
available for 87/107 (81%) children. The 20 children with
missing test results were similarly distributed across first-line
regimen and randomized switch thresholds (x2 on 3 degrees
of freedom P = 0.76). For 87 children with available
resistance tests on first-line, median time from randomiza-
tion to last resistance test was 72 weeks in the low-threshold
and 124 weeks in the higher-threshold arm (Wilcoxon rank-
sum P = 0.009). For PIs, this was 50 versus 121 weeks (P =
0.01) and for NNRTIs, 95 versus 148 weeks (P = 0.35).
HIV-1 Resistance Mutations Accumulated on
First-Line ART
Table 2 displays new major International AIDS
Society-USA resistance mutations accumulated on first-
line. More NRTI mutations accumulated in NNRTI-higher
than the other 3 groups, with more children selecting $3
mutations in NNRTI-higher driving this difference (Poisson
P , 0.001). Overall, more NNRTI than PI mutations
accumulated (Poisson P , 0.001). It seemed that NNRTI
mutations had already been selected before switching at the
“1000 criteria” as NNRTI-low had a similar number of
mutations to NNRTI-higher. PI mutations were developed
by 16% in PI-low and 7% in PI-higher; note more nelfinavir
was administered in PI-low. For nonrandomized NRTIs, 5
(9%) on abacavir + lamivudine, 39 (25%) on lamivudine +
zidovudine or stavudine, and 6 (21%) on other NRTI
combinations developed mutations (Poisson P , 0.01).
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TABLE 1. Baseline Age, HIV-1 RNA, IAS Resistance Mutations, HIV-1 Subtype, ART for Reduction of MTCT and First-Line ART by
Randomized Switch Threshold
Randomized Switch Threshold
Total (n = 263)Low (n = 134) Higher (n = 129)
Age (yrs), median (IQR) [range] 6.1 (2.5–13.1) [0.3–17.8] 6.9 (3.1–12.5) [0.1–17.5] 6.5 (2.8–12.9) [0.1–17.8]
HIV-1 RNA (copies/mL), median (IQR) 99,646 (35,488–446,704) 119,356 (28,732–434,369) 107,813 (31,251–446,704)
Baseline resistance test available* 121 (100%) 118 (100%) 239 (100%)
Any major mutations 7 (6%) 3 (3%) 10 (4%)
1 or 2 mutations 7 2 9
$3 mutations 0 1 1
NNRTI K103N 1 1 2
NNRTI V108I 1 0 1
NNRTI Y181C 2 1 3
NNRTI Y188L 1 0 1
PI Q58E 1 0 1
NNRTI K101P Y181C 1 0 1
NRTI D67N K219Q, NNRTI K103N 0 1 1
HIV-1 subtype available,† 128 (100%) 121 (100%) 249 (100%)
HIV-1 subtype
B 52 (41%) 49 (41%) 101 (41%)
C 13 (10%) 12 (10%) 25 (10%)
F 25 (20%) 23 (19%) 48 (19%)
A/CRF_AG/D/G 25 (20%) 27 (22%) 52 (21%)
Unclassified 13 (10%) 10 (8%) 23 (9%)
ART use before randomization for reduction of MTCT‡ 22 (100%) 17 (100%) 39 (100%)
In utero (to the mother) 4 (18%) 6 (35%) 10 (26%)
1 d ZDV + NVP 0 1 1
1–24 wks ZDV + 3TC + NVP 2 2 4
1–2 wks ZDV + 3TC + NFV 1 1 2
7–28 wks ZDV 1 2 3
Delivery/postpartum (to the infant) 22 (100%) 16 (94%) 38 (97%)
Single-dose NVP, 1–4 wks ZDV + 3TC 0 2 2
Single-dose NVP, 3–6 wks ZDV 2 1 3
1–12 wks ZDV 19 12 31
5–6 wks ZDV, 3–6 wks 3TC 1 1 2
First-line NNRTI ART 67 (100%) 65 (100%) 132 (100%)
EFV with 43 (64%) 39 (60%) 82 (62%)
ABC + 3TC 15 10 25
ZDV + 3TC 17 18 35
d4T + 3TC 6 3 9
Other NRTIs§ 5 8 13
NVP with 24 (36%) 26 (40%) 50 (38%)
ABC + 3TC 3 6 9
ZDV + 3TC 15 11 26
d4T + 3TC 3 8 11
Other NRTIsk 3 1 4
First-line PI ART 67 (100%) 64 (100%) 131 (100%)
LPV/r with 29 (43%) 36 (56%) 65 (50%)
ABC + 3TC 10 12 22
ZDV + 3TC 10 20 30
d4T + 3TC 6 4 10
Other NRTIs¶ 3 0 3
NFV with 37 (55%) 27 (42%) 64 (49%)
ABC + 3TC 3 3 6
ZDV + 3TC 12 9 21
d4T + 3TC 13 10 23
(continued on next page)
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Figure 2 provides a detailed description of first-line ART
administered and mutations accumulated. It reveals, in PI-low
and PI-higher, very few PI mutations were selected by children
on lopinavir/ritonavir and relatively more on nelfinavir. On
lopinavir/ritonavir, the main NRTI mutation selected was
M184V, but on nelfinavir, additional NRTI mutations were
accumulated. All 5 children who developed NRTI mutations
on abacavir + lamivudine were on NNRTIs, whereas 22/39
(56%) children on lamivudine + zidovudine or stavudine with
mutations were on NNRTIs and 17/39 (44%) on PIs.
Susceptibility to Potential Second-Line ART
Figure 3 displays susceptibility to potential second-line
regimens. All children on first-line abacavir + lamivudine
with lopinavir/ritonavir were fully susceptible to WHO
recommended second-line lamivudine + zidovudine with
efavirenz in PI-low and PI-higher. Eleven (73%) in PI-low
and 20 (87%) in PI-higher were fully susceptible to WHO
recommended second-line after first-line lamivudine + zido-
vudine or stavudine with lopinavir/ritonavir. After first-line
abacavir + lamivudine with an NNRTI, 14 (82%) in NNRTI-
low and 12 (80%) in NNRTI-higher were fully susceptible to
second-line lamivudine + zidovudine with lopinavir/ritonavir.
After first-line lamivudine + zidovudine or stavudine with an
NNRTI, 32 (80%) in NNRTI-low and 26 (65%) in NNRTI-
higher were fully susceptible to second-line lamivudine +
abacavir or tenofovir with lopinavir/ritonavir. This likely
reflects accumulation of thymidine analog mutations (TAMs)
on zidovudine or stavudine.
TABLE 1. (Continued ) Baseline Age, HIV-1 RNA, IAS Resistance Mutations, HIV-1 Subtype, ART for Reduction of MTCT and First-
Line ART by Randomized Switch Threshold
Randomized Switch Threshold
Total (n = 263)Low (n = 134) Higher (n = 129)
Other NRTIs# 9 5 14
Other PI 1 (1%) 1 (2%) 2 (2%)
ZDV + 3TC + high-dose ritonavir 0 1 1
ddI + 3TC + fosamprenavir/ritonavir 1 0 1
Children are displayed in 2 groups defined by their randomized switch threshold (low = 1000 copies/mL, higher = 30,000 copies/mL).
*Includes 1 test where only the protease gene was sequenced.
†Available from 239 baseline resistance tests and 10 resistance tests during follow-up.
‡For 3/5 children who received single-dose NVP, the mother also received NVP in utero.
§10 ZDV + ddI, 2 3TC + ddI, 1 ddI + FTC.
k1 ZDV + ddI, 1 ZDV + ABC, 2 ddI + d4T.
¶1 ZDV + ddI, 2 ZDV + ABC.
#13 ZDV + ddI, 1 ddI + d4T.
3TC, lamivudine; ABC, abacavir; d4T, stavudine; ddI, didanosine; EFV, efavirenz; FTC, emtricitabine; IAS, International AIDS Society-USA; IQR, interquartile range; LPV/r,
lopinavir/ritonavir; MTCT, mother-to-child transmission; NFV, nelfinavir; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; ZDV, zidovudine.
FIGURE 1. Kaplan–Meier curves displaying the time from reaching the 1000 criteria to switch in the low-threshold arm (solid
line), time from the 1000 criteria to the 30,000 criteria in the higher-threshold arm (dotted dashed line), and time from the 1000
criteria to switch in the higher-threshold arm (solid dashed line) by first-line NNRTI-based (A) or PI-based ART (B). The 1000
criteria were defined as not achieving HIV-1 RNA ,1000 copies/mL by week 24, confirmed rebound $1000 copies/mL thereafter
or Center for Disease Control and Prevention (CDC) stage C event. The 30,000 criteria were defined as not achieving HIV-1 RNA
,30,000 copies/mL by week 24, confirmed rebound $30,000 copies/mL thereafter or CDC stage C event. Children in the low-
threshold arm were randomized to switch at the 1000 criteria, and those in the higher-threshold arm to switch at the 30,000
criteria. Ninety-four children reached the 1000 criteria during the trial, but 93 children are displayed in the figure as 1 child on PI-
based first-line ART randomized to switch at the low-threshold ended follow-up on the same day as reaching the 1000 criteria.
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Second-Line Response
Sixty children switched to second-line during
PENPACT-1 (20 PI-low, 8 PI-higher, 17 NNRTI-low, 15
NNRTI-higher). Five switched before reaching the “1000
criteria” (3 low threshold, 2 higher threshold) and 55 (34
low threshold, 21 higher threshold) after they were met; 18
of the 21 in the higher-threshold arm waited until the
“30,000 criteria” were met, but 3 did not. The proportion
,400 copies/mL by 24 weeks on second-line was 79% in
PI-low, 63% PI-higher, 64% NNRTI-low, and 100%
NNRTI-higher (Cox regression P = 0.10). Of 46/60
children with resistance data on first-line, 18 (39%) had
no NRTI mutations, 22 (48%) 1–2 NRTI mutations, and 6
(13%) $3 NRTI mutations (all 6 were in NNRTI-higher).
Of those without NRTI resistance, 93% suppressed to
,400 copies/mL by 24 weeks on second-line, whereas for
those with 1–2 NRTI mutations, 65% suppressed, and those
with $3 NRTI mutations, 100% suppressed (Cox regres-
sion P = 0.64). The Supplemental Digital Content list
(http://links.lww.com/QAI/A682) provides a detailed
description of these children.
DISCUSSION
Throughout the world, children continue to initiate both
NNRTI- and PI-based first-line regimens in national treatment
programs. Our long-term trial including a wide age range of
children starting first-line PIs and NNRTIs provided a unique
opportunity to study development of HIV-1 drug resistance and
gain insight into resistance consequences of different ART
switching strategies. Overall and as predicted, we found that
children starting NNRTIs accumulated more HIV-1 drug
resistance than those starting PIs. In particular, children switch-
ing later on NNRTIs accumulated more NRTI mutations,
whereas on PIs, NRTI mutations did not accumulate over the
time taken to reach a 30,000 copies/mL threshold. Children
taking the currently recommended lopinavir/ritonavir selected
even fewer mutations than those on the unboosted PI, nelfinavir,
which is no longer recommended. Furthermore, in this study,
before tenofovir was available in children (now approved by the
FDA for children .2 years), there was a resistance benefit for
children prescribed first-line abacavir + lamivudine compared
with lamivudine + zidovudine or stavudine, but randomized
evidence to verify this finding is required.
TABLE 2. Major IAS Resistance Mutations Accumulated on First-Line ART
PI-Low PI-Higher NNRTI-Low NNRTI-Higher Poisson P*
Total children 67 64 67 65
Number requiring tests† 34 22 26 25
Number with test results 28 17 20 22
Included in analysis* 61 59 61 62
NRTI resistance, %
1 or 2 mutations 11 (18) 7 (12) 12 (20) 12 (19) any difference
$3 mutations 0 (0) 1 (2) 0 (0) 7 (11) ,0.001
PI or NNRTI resistance, %
1 or 2 mutations 10 (16) 4 (7) 13 (21) 12 (19) PI versus NNRTI
$3 mutations 0 (0) 0 (0) 1 (2) 5 (8) ,0.001
ABC + 3TC 3TC + ZDV/d4T Other (Mainly ZDV + ddI) Poisson P*
Total children 62 166 35
Number requiring tests† 15 67 25
Number with test results 9 59 19
Included in analysis* 56 158 29
NRTI resistance, %
1 or 2 mutations 4 (7) 32 (20) 6 (21) Any difference
$3 mutations 1 (2) 7 (4) 0 (0) ,0.01
TAMs, %
1 or 2 TAMs 0 (0) 6 (4) 6 (21)
$3 TAMs 0 (0) 4 (3) 0 (0)
K65R 1 (2) 0 (0) 0 (0)
L74R 1 (2) 1 (1) 0 (0)
Y115F 1 (2) 0 (0) 0 (0)
M184V/I 5 (9) 39 (25) 0 (0)
Children are displayed in 4 groups defined by the class of ART initiated as first-line (PI-based versus NNRTI-based) and their randomized switch threshold (low = 1000 copies/mL,
higher = 30,000 copies/mL).
*Analysis assumes those not requiring tests were not resistant and excludes those with unavailable resistance results.
†Resistance tests were required on first-line, while children were on ART, at (1) the last sample with RNA $1000 copies/mL before switch, (2) the last sample after confirmed
RNA $1000 copies/mL (eg, if not switched because 30,000 criteria not met and RNA resuppressed to ,1000 copies/mL), and (3) samples with RNA $1000 copies/mL at 4 years or
trial end. IAS major resistance mutations were accumulated across multiple tests per child on first-line, where appropriate. The table displays number of children requiring tests and the
number of children with test results, rather than the absolute number of tests performed.
3TC, lamivudine; ABC, abacavir; d4T, stavudine; ddI, didanosine; IAS, International AIDS Society-USA; NRTI, nucleoside reverse transcriptase inhibitor; ZDV, zidovudine.
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Over approximately 5 years on ART, suppression on
first-line regimens was good with only around one-third of
children ever reaching the “1000 criteria” for switch. Of
those, the observed time from 1000 to “30,000 criteria” was
slightly longer for NNRTIs compared with PIs, but time
from “1000 criteria” to switch was longer for PIs than
NNRTIs. This suggests children failing on NNRTIs spent a
slightly longer time with RNA between 1000 and
FIGURE 2. Major IAS resistance mutations accumulated on first-line ART. Children are displayed in 4 groups defined by the
class of ART initiated as first-line (PI based versus NNRTI based) and their randomized switch threshold (low = 1000 copies/mL
versus higher = 30,000 copies/mL). Resistance tests were required on first-line in both randomized switch threshold arms, while
children were on ART, at (1) the last sample with RNA $1000 copies/mL before switch, (2) the last sample after confirmed RNA
$1000 copies/mL (eg, if not switched because 30,000 criteria not met and RNA resuppressed to ,1000 copies/mL), and (3)
samples with RNA $1000 copies/mL at 4 years or trial end. 3TC, lamivudine; ABC, abacavir; d4T, stavudine; ddI, didanosine;
EFV, efavirenz; IAS, International AIDS Society-USA; LPV/r, lopinavir/ritonavir; NFV, nelfinavir; NRTI, nucleoside reverse tran-
scriptase inhibitor; NVP, nevirapine; RTV, high-dose ritonavir; ZDV, zidovudine.
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30,000 copies/mL with prompt switch once the “30,000
criteria” were met. In contrast, children on PIs spent
a slightly shorter time with RNA between 1000 and
30,000 copies/mL, but the treating clinician had a tendency
to wait to switch after the “30,000 criteria” were met,
possibly due to assessment of adequate adherence before
switching to an NNRTI-based second-line. Despite this
tendency to wait to switch on PIs, which hypothetically
would result in more resistance mutations, we still saw less
resistance accumulate in PI-higher compared with NNRTI-
higher. These data are consistent with clinical trials and
observational studies in adults, reporting fewer NRTI
mutations on PIs than NNRTIs,8,9 as well as additional reports
on accumulation of NRTI resistance on NNRTIs.10–12
As well as the overall protective effect of PIs, we saw
fewer NRTI and PI resistance mutations for children on the
boosted PI lopinavir/ritonavir compared with other PIs
(mainly unboosted nelfinavir). This is consistent with a sys-
tematic review of drug resistance after first-line failure in
children,13 which observed that the type of PI affected
development of resistance. In particular, on nelfinavir, where
adequate plasma concentrations are seldom reached in
children,14 D30N and N88S, specific nelfinavir mutations,
were frequently reported. The review did not describe NRTI
FIGURE 3. Second-line ART options. Children are displayed in 4 groups defined by the class of ART initiated as first-line (PI based
versus NNRTI based) and their randomized switch threshold (low = 1000 copies/mL versus higher = 30,000 copies/mL). The
clinician chosen initial first-line ART is displayed along with current WHO recommended second-line and the susceptibility to this
potential second-line regimen by the Stanford algorithm. The proportion of children susceptible to the potential second-line
options assumed that children not meeting requirements for resistance testing were susceptible and excludes children with
unavailable resistance results. Second-line containing EFV is only recommended for children .3 years and has been noted on the
figure. 3TC, lamivudine; ABC, abacavir; d4T, stavudine; ddI, didanosine; EFV, efavirenz; FOS/r, fosamprenavir/ritonavir; FTC,
emtricitabine; LPV/r, lopinavir/ritonavir; NFV, nelfinavir; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; RTV,
high-dose ritonavir; TDF, tenofovir; ZDV, zidovudine.
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mutations by PI exposure, but our data suggest PI choice is
likely to be important as lopinavir/ritonavir seemed particu-
larly protective against accumulation of NRTI mutations. This
is supported by CHER trial data15 where only 11/331 (3%)
children initiating lopinavir/ritonavir based first-line devel-
oped NRTI mutations, 10 of which developed M184V alone
and no TAMs were seen.
To our knowledge, PENPACT-1 is the only trial of
randomized criteria for switching from first- to second-line
ART based on RNA thresholds. There has been 1 small
short-term trial where highly ART experienced adults were
randomized to immediate or deferred switch,16 and 2 trials
comparing monitoring strategies with resistance data by
arm.17,18 In the small ART experienced trial,16 median time
to meeting criteria was .60 weeks suggesting a similar
delayed switch time to our study. A trend toward more new
mutations in the deferred-switch compared with the
immediate-switch arm was observed, with most new muta-
tions to NRTIs, particularly TAMs. However, particular
drugs or drug classes could not be assessed. The first
monitoring trial17 compared CD4 with RNA monitoring
and revealed no difference in a future drug options score
between arms. However, more patients in the CD4 arm,
which had a longer duration .400 copies/mL, had$3 NRTI
mutations. The only 2 patients who developed TAMs were
in the CD4 arm. These data are consistent with our study,
showing a low barrier to development of lamivudine and
NNRTI resistance, which is similar in the 2 arms, but
documentation of TAM accumulation in the arm with longer
duration of virologic failure. The other monitoring trial,18
compared laboratory and clinical monitoring to clinical
monitoring alone, and showed a similar number of patients
with major mutations in the clinical monitoring alone versus
the laboratory and clinical monitoring arm. The authors
noted that switching occurred late after first detectable RNA
in the laboratory and clinical monitoring arm, which may
account for the fact no differences were seen.
Since the advent of triple therapy, 2 randomized
trials19,20 on NRTI backbones in children suggest abacavir +
lamivudine has similar or better efficacy compared with other
NRTI combinations. Our data add to the current weight of
evidence that prescribing an NRTI backbone of abacavir +
lamivudine first-line followed by zidovudine in second-line
has some resistance advantages, as previously described in the
PENTA-5 trial.21 For children prescribed abacavir + lamivu-
dine in combination with lopinavir/ritonavir, we did not detect
any resistance, and in combination with NNRTIs, we only saw
5 children with NRTI resistance. The abacavir-specific
mutations do not affect susceptibility to second-line zidovu-
dine, and there is evidence that K65R induces hypersuscep-
tibility to zidovudine.22 Conversely, using zidovudine (or
stavudine) first-line results in accumulation of TAMs such that
the efficacy of abacavir second-line is reduced. Overall
accumulation of NRTI resistance on lamivudine + zidovudine
or stavudine was greater than on abacavir + lamivudine with
TAMs occurring in 10 children (including 1 on lopinavir/
ritonavir), suggesting abacavir + lamivudine has beneficial
resistance properties when prescribed first-line with lopinavir/
ritonavir or NNRTIs. More than 2 TAMs accumulated for
4 children on lamivudine + zidovudine or stavudine and 5
children developed mutations from the TAM type 1 pathway,
which is known to have a negative impact on response to
abacavir.22 In addition, the M184V mutation, present in nearly
all children developing resistance on first-line, increases
susceptibility to thymidine analogs (zidovudine and stavudine)
but causes low-level resistance to abacavir.22 Therefore, these
data support a resistance benefit of prescribing abacavir +
lamivudine first-line in settings where children may spend
longer with high RNAs due to limited laboratory monitoring
or unavailable second-line regimens.
Our data on efficacy of second-line are limited by the
small number of children switching by trial end. However, the
data suggest a similar (or maybe better) suppression rate after
failing in the NNRTI-higher arm. The effect of NRTI resistance
before switch on second-line efficacy revealed a consistent
pattern, suggesting children who had developed 1–2 NRTI
mutations on first-line did worst and those with $3 mutations
best. In our data, there was no evidence that clinicians selected
more potent second-line regimens for children known to be
failing with extensive resistance, so one could hypothesize that
a boosted PI with partially effective NRTIs is sufficiently potent
to suppress virus at least until week 24 of second-line.
Alternatively, it may be that adherence more than drug resistance
influences second-line success; 2 studies in adults23,24 with
resistance tests before switch from an NNRTI- to PI-based ART
found either no association of NRTI resistance with the success
of second-line or paradoxically a higher suppression rate in those
with resistance. The authors of the second study found evidence
from pharmacokinetic drug levels that it was indeed adherence
rather than drug resistance that influenced second-line success.
CONCLUSIONS
This study confirms the protective effect of a boosted PI
against accumulation of HIV-1 drug resistance mutations, as
reported in adult studies. Analysis of nonrandomized NRTI
backbones suggests that abacavir + lamivudine results in
fewer resistance mutations than lamivudine + zidovudine or
stavudine, whether prescribed with an NNRTI or lopinavir/
ritonavir. Overall, these data support WHO 2013 pediatric
guidelines1 recommending abacavir + lamivudine as the first-
line NRTI backbone with an NNRTI and provide reassurance
that despite the possibility of considerable time spent on first-
line with detectable viremia (where HIV-1 RNA monitoring
is not available), response to second-line with a boosted PI
and zidovudine + lamivudine is expected to be good.
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D. Beniken (L), and G. Alexandre-Castor (L).
Germany
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Universitäts—Kinderkliniken, Munich: G. Notheis, U. Wintergerst, and
F. Hoffman, (A. Werthmann, S. Seyboldt, L. Schneider, B. Bucholz);
Charité—Medizische Fakultät der Humboldt-Universität zu Berlin:
C. Feiterna-Sperling, C. Peiser, R. Nickel, T. Schmitz, T. Piening, and
C. Müller (L); Kinder-und Jugendklinik, Universität Rostock: G. Warncke,
M. Wigger, and R. Neubauer.
Ireland
Our Lady’s Hospital for Sick Children, Dublin: K. Butler, A. L.
Chang, T. Belger, A. Menon, M. O’Connell, L. Barrett, A. Rochford,
M. Goode, E. Hayes, S. McDonagy, A. Walsh, A. Doyle, J. Fanning (P),
M. O’Connor (P), M. Byrne (L), N. O’Sullivan (L), and E. Hyland (L).
Italy
Clinica Pediatrica, Ospedale L. Sacco, Milan: V. Giacomet,
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